CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer

被引：32

作者：

Hlevnjak, Mario ^{[1
,2
]}

Schulze, Markus ^{[1
,2
]}

Elgaafary, Shaymaa ^{[2
,3
,4
]}

Fremd, Carlo ^{[3
,4
]}

Michel, Laura ^{[3
,4
]}

Beck, Katja ^{[2
,5
]}

Pfuetze, Katrin ^{[2
]}

Richter, Daniela ^{[6
]}

Wolf, Stephan ^{[7
]}

Horak, Peter ^{[5
]}

Kreutzfeldt, Simon ^{[2
,5
]}

Pixberg, Constantin ^{[2
,3
,4
]}

Hutter, Barbara ^{[2
,8
]}

Ishaque, Naveed ^{[9
]}

Hirsch, Steffen ^{[10
]}

Gieldon, Laura ^{[10
]}

Stenzinger, Albrecht ^{[11
]}

Springfeld, Christoph ^{[12
]}

Smetanay, Katharina ^{[3
,4
]}

Seitz, Julia ^{[3
,4
]}

Mavratzas, Athanasios ^{[3
,4
]}

Brors, Benedikt ^{[8
]}

Kirsten, Romy ^{[13
]}

Schuetz, Florian ^{[14
]}

Froehling, Stefan ^{[5
]}

Sinn, Hans-Peter ^{[11
]}

Jaeger, Dirk ^{[12
]}

Thewes, Verena ^{[1
,3
,4
]}

Zapatka, Marc ^{[1
]}

Lichter, Peter ^{[1
,9
]}

Schneeweiss, Andreas ^{[3
,4
]}

机构：

[1] German Canc Consortium DKTK, Div Mol Genet, German Canc Res Ctr DKFZ, Heidelberg, Germany

[2] Natl Ctr Tumor Dis NCT Heidelberg, Mol Diagnost Program, Heidelberg, Germany

[3] Heidelberg Univ, Natl Ctr Tumor Dis NCT, Gynecol Oncol, Heidelberg, Germany

[4] German Canc Res Ctr, Heidelberg, Germany

[5] German Canc Res Ctr, Natl Ctr Tumor Dis NCT Heidelberg, Dept Translat Med Oncol, Heidelberg, Germany

[6] German Canc Res Ctr, Natl Ctr Tumor Dis NCT Dresden, Dept Translat Med Oncol, Heidelberg, Germany

[7] German Canc Res Ctr, Genom & Prote Core Facil, Heidelberg, Germany

[8] German Canc Res Ctr, Div Appl Bioinformat, Heidelberg, Germany

[9] German Canc Res Ctr, Heidelberg Ctr Personalized Oncol DKFZ HIPO, Heidelberg, Germany

[10] Univ Hosp Heidelberg, Inst Human Genet, Heidelberg, Germany

[11] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany

[12] Univ Hosp Heidelberg, Natl Ctr Tumor Dis NCT, Dept Med Oncol, Heidelberg, Germany

[13] Natl Ctr Tumor Dis NCT, Liquid Biobank, Heidelberg, Germany

[14] Heidelberg Univ Hosp, Dept Gynecol & Obstet, Heidelberg, Germany

来源：

JCO PRECISION ONCOLOGY | 2021年 / 5卷

关键词：

MULTICENTER; COMBINATION; MEDICINE; EFFICACY; THERAPY;

D O I：

10.1200/PO.20.00248

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSE CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics and transcriptomics to guide therapeutic decisions in the clinical management of metastatic breast cancer. Herein, we report our single-center experience and results on the basis of the first 200 enrolled patients of an ongoing trial. METHODS From June 2017 to March 2019, 200 patients who had either primary metastatic or progressive disease, with any number of previous treatment lines and at least one metastatic site accessible to biopsy, were enrolled. DNA and RNA from tumor tissue and corresponding blood-derived nontumor DNA were profiled using whole-genome and transcriptome sequencing. Identified actionable alterations were brought into clinical context in a multidisciplinary molecular tumor board (MTB) with the aim of prioritizing personalized treatment recommendations. RESULTS Among the first 200 enrolled patients, 128 (64%) were discussed in the MTB, of which 64 (50%) were subsequently treated according to MTB recommendation. Of 53 evaluable patients, 21 (40%) achieved either stable disease (n = 13, 25%) or partial response (n = 8, 15%). Furthermore, 16 (30%) of those patients showed improvement in progression-free survival of at least 30% while on MTB-recommended treatment compared with the progression-free survival of the previous treatment line. CONCLUSION The initial phase of this study demonstrates that precision oncology on the basis of whole-genome and RNA sequencing is feasible when applied in the clinical management of patients with metastatic breast cancer and provides clinical benefit to a substantial proportion of patients.

引用

页码：676 / 686

页数：11

共 50 条

[41] Randomised trial of expressive writing for distressed metastatic breast cancer patients [J].

Mosher, Catherine E. ;

DuHamel, Katherine N. ;

Lam, Joanne ;

Dickler, Maura ;

Li, Yuelin ;

Massie, Mary Jane ;

Norton, Larry .

PSYCHOLOGY & HEALTH, 2012, 27 (01) :88-100

[42] Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial [J].

Armstrong, Andrew J. ;

Humeniuk, Michael S. ;

Healy, Patrick ;

Szmulewitz, Russell ;

Winters, Carolyn ;

Kephart, Julie ;

Harrison, Michael R. ;

Martinez, Elia ;

Mundy, Kelly ;

Halabi, Susan ;

George, Daniel .

PROSTATE, 2017, 77 (04) :385-395

[43] Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802) [J].

Katsumata, N. ;

Watanabe, T. ;

Minami, H. ;

Aogi, K. ;

Tabei, T. ;

Sano, M. ;

Masuda, N. ;

Andoh, J. ;

Ikeda, T. ;

Shibata, T. ;

Takashima, S. .

ANNALS OF ONCOLOGY, 2009, 20 (07) :1210-1215

[44] The NCI-MATCH trial: lessons for precision oncology [J].

O'Dwyer, Peter J. ;

Gray, Robert J. ;

Flaherty, Keith T. ;

Chen, Alice P. ;

Li, Shuli ;

Wang, Victoria ;

McShane, Lisa M. ;

Patton, David R. ;

Tricoli, James V. ;

Williams, P. Mickey ;

Iafrate, A. John ;

Sklar, Jeffrey ;

Mitchell, Edith P. ;

Takebe, Naoko ;

Sims, David J. ;

Coffey, Brent ;

Fu, Tony ;

Routbort, Mark ;

Rubinstein, Larry V. ;

Little, Richard F. ;

Arteaga, Carlos L. ;

Marinucci, Donna ;

Hamilton, Stanley R. ;

Conley, Barbara A. ;

Harris, Lyndsay N. ;

Doroshow, James H. .

NATURE MEDICINE, 2023, 29 (6) :1349-1357

[45] Study of Low-Dose Capecitabine Monotherapy for Metastatic Breast Cancer [J].

Taguchi, Tetsuya ;

Nakayama, Takahiro ;

Masuda, Norikazu ;

Yoshidome, Katsuhide ;

Akagi, Kenzou ;

Nishida, Yukihiro ;

Yoshikawa, Yukinobu ;

Ogino, Nobuo ;

Abe, Chigusa ;

Sakamoto, Junichi ;

Noguchi, Shinzaburo .

CHEMOTHERAPY, 2010, 56 (02) :166-170

[46] Visceral crisis in metastatic breast cancer: an old concept with new perspectives [J].

Andrade, Matheus de Oliveira ;

Bonadio, Renata Rodrigues da Cunha Colombo ;

Diz, Maria Del Pilar Estevez ;

Testa, Laura .

CLINICS, 2024, 79

[47] Taxanes as a First-Line Systemic Treatment in Metastatic Breast Cancer [J].

Urquhart, Laura M. .

CLINICAL JOURNAL OF ONCOLOGY NURSING, 2013, 17 (01) :15-21

[48] A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology [J].

Guillen, Katrin P. ;

Fujita, Maihi ;

Butterfield, Andrew J. ;

Scherer, Sandra D. ;

Bailey, Matthew H. ;

Chu, Zhengtao ;

DeRose, Yoko S. ;

Zhao, Ling ;

Cortes-Sanchez, Emilio ;

Yang, Chieh-Hsiang ;

Toner, Jennifer ;

Wang, Guoying ;

Qiao, Yi ;

Huang, Xiaomeng ;

Greenland, Jeffery A. ;

Vahrenkamp, Jeffery M. ;

Lum, David H. ;

Factor, Rachel E. ;

Nelson, Edward W. ;

Matsen, Cindy B. ;

Poretta, Jane M. ;

Rosenthal, Regina ;

Beck, Anna C. ;

Buys, Saundra S. ;

Vaklavas, Christos ;

Ward, John H. ;

Jensen, Randy L. ;

Jones, Kevin B. ;

Li, Zheqi ;

Oesterreich, Steffi ;

Dobrolecki, Lacey E. ;

Pathi, Satya S. ;

Woo, Xing Yi ;

Berrett, Kristofer C. ;

Wadsworth, Mark E. ;

Chuang, Jeffrey H. ;

Lewis, Michael T. ;

Marth, Gabor T. ;

Gertz, Jason ;

Varley, Katherine E. ;

Welm, Bryan E. ;

Welm, Alana L. .

NATURE CANCER, 2022, 3 (02) :232-+

[49] A Phase II Trial of Onapristone and Fulvestrant for Patients With ER + and HER2-Metastatic Breast Cancer [J].

Kamaraju, Sailaja ;

Fowler, Amy M. ;

Tarima, Sergey ;

Chaudhary, Lubna N. ;

Burkard, Mark E. ;

Giever, Thomas ;

Cheng, Yee C. ;

Parkes, Amanda ;

Lange, Carol A. ;

Pipp-Dahm, Michele ;

Hegeman, Robert ;

Siddiqui, Nauman ;

Stella, Amy ;

Rajguru, Saurabh ;

Twaroski, Kyleigh ;

Zurbriggen, Luke ;

Jorns, Julie M. ;

Rui, Hallgeir ;

Keigley, Quinton J. ;

Perlman, Scott B. ;

Salem, Kelley ;

Bradshaw, Tyler J. ;

Sahmoud, Tarek ;

Wisinski, Kari .

CLINICAL BREAST CANCER, 2025, 25 (03) :251-260

[50] Phase II Trial of Loubo® (Lobaplatin) and Pemetrexed for Patients with Metastatic Breast Cancer not Responding to Anthracycline or Taxanes [J].

Deng, Qian-Qian ;

Huang, Xin-En ;

Ye, Li-Hong ;

Lu, Yan-Yan ;

Liang, Yong ;

Xiang, Jin .

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (01) :413-417

← 1 2 3 4 5 →